Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market

Q: How big was the global non-small cell Lung cancer (NSCLC) therapeutics market in 2024?

It was valued at US$ 22.3 Bn in 2024 Read More

Q: What is the projected size of the non-small cell Lung cancer (NSCLC) therapeutics market by 2035?

It is projected to cross US$ 81.9 Bn by the end of 2035 Read More

Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market (Therapy Type: Targeted Therapy, Immunotherapy and Chemotherapy; Drug Class: Vascular Endothelial Growth Factor (VEGF) Inhibitors, KRAS Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Anaplastic lymphoma kinase (ALK) Inhibitors, ROS1 Inhibitors, BRAF Inhibitors, MET Inhibitors and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025–2035

Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Outlook 2035

The global non-small cell lung cancer (NSCLC) therapeutics market size was valued at US$ 22.3 billion in 2024 and is projected to reach US$ 81.9 billion by 2035, expanding at a CAGR of 12.6% from 2025 to 2035. The market growth is driven by advancements in targeted therapies and regulatory approvals and fast-track designations.

Market Size & Highlights

The non-small cell lung cancer (NSCLC) therapeutics market reached US$ 22.3 Billion in 2024.
The market is expected to climb to US$ 81.9 Billion by 2035.
The industry is anticipated to expand at a CAGR of 12.6% from 2025 to 2035.
Top companies in the market include F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen Inc., Bristol Myers Squibb, Boehringer Ingelheim International GmbH, etc.
North America dominated the market in 2024, holding the largest revenue share of 40.2%.
By therapy type, the targeted therapy segment held the major market share of 47.8% in 2024.

Non Small Cell Lung Cancer Therapeutics Market By Revenue

Analysts’ Viewpoint regarding Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market

The NSCLC (Non-Small Cell Lung Cancer) therapeutics market is undergoing substantial expansion. This expansion is mainly fueled by the progression of treatment choices and deepening comprehension of the disease at a molecular level. As a result, NSCLC, which makes up about 85% of lung cancer cases, has moved away from the use of traditional chemotherapy toward targeted therapies and immunotherapies. These inventions, such as immune checkpoint inhibitors and targeted agents that primarily focus on genetic mutations, have not only made patients healthier but also survival rates longer.

The market is being characterized by growing expenditure on research and development activities, as pharmaceutical companies compete to be the first in introducing novel therapies to the market. On top of that, the concept of personalized medicine has been a pivotal factor leading to tailor-made treatment regimens based on the genetic profiles of each patient, thereby making drug therapy more effective.

Developing countries are also experiencing a growing demand for NSCLC treatment, as the smoking habits and pollution, which are major causes of lung cancer, increase in these regions. Besides, the elderly population is becoming a significant contributor to the rise in lung cancer cases.

Nevertheless, the situation in terms of high treatment costs and the need for continuous innovation to solve the problem of resistance to existing therapies, still exists. In general, the NSCLC therapeutics market is still on the way to further development and likely be able to offer revolutionary treatments that could change the level of care for patients globally.

Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Introduction

Non-small cell lung cancer (NSCLC) is the primary type of lung cancer, which makes up approximately 85% of the total cases. It is composed of several subtypes that mainly include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. NSCLC generally originates from the epithelial cells in the lungs and is commonly associated with the aforementioned risk factors of smoking, exposure to secondhand smoke, and inhalation of air pollutants. The early stage of NSCLC is asymptomatic in most cases; therefore, the diagnosis is usually made at advanced stages with a consequent worse prognosis.

Research in medicine has played a major role in deepening the knowledge and improving the treatment of NSCLC. Along with the standard treatments like the three surgical interventions, chemotherapy, and radiation therapy, targeted therapies and immunotherapies have recently been introduced as new options that have changed the outcomes of patients dramatically. The primary goal of targeted therapies is to interfere with the cancer growth-specific molecular targets, while immunotherapies impact the body's defense mechanism against cancer cells.

In spite of all these progresses, there are still some issues such as expensive treatments, the necessity for individualized therapeutic regimens, and the possibility of resistance to therapies. The research and clinical trials to be conducted are important for finding out new drugs and elevating the survival rates. The situation around NSCLC treatment, in fact, is changing due to this research, and this may give a chance to better cope with the disease.

Attribute	Detail
Market Drivers	Advancements in Targeted Therapies Increasing Incidence of Lung Cancer Regulatory Approvals and Fast-Track Designations

Advancements in Targeted Therapies Expected to Drive Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Size

The NSCLC therapeutics market is mainly influenced by the prominent role played by one of its most significant segments, targeted therapies, which have basically evolved the treatment paradigms for this widely spread cancer type. Targeted therapies zero in on specific molecular changes in cancer cells, thereby enabling more accurate and efficient methods. For instance, tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib, which are directed against mutations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors, generally alleviate the condition of patients with ALK rearrangements.

The improvements of targeted therapies have led to increased expenditure on biomarker testing, aiming at providing clinicians with tools to spot the right candidates and customize the treatments accordingly. This personalized approach makes the treatment more effective and at the same time, prevents patients from being unnecessarily exposed to a treatment that is ineffective.

Besides, incessant research is progressively revealing so many genetic targets that henceforth become new therapeutic options. Therefore, the Non-Small Cell Lung Cancer (NSCLC) Therapeutics market is flourishing loudly due to the increasing use of these revolutionary drug regimens.

Regulatory Approvals and Fast-Track Designations Anticipated to Boost Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Expansion

The authorities in charge of drug regulation, like the U.S. Food and Drug Administration (FDA), have set ways to speed up the granting of the first therapy innovations having promising efficacy and safety data. Thus, the Breakthrough Therapy Designation and Priority Review programs are most meaningful, as they enable the developers in the field to bring the most life-saving therapies to the market in shortest periods of time.

Besides, these fast-track designations limit the duration of clinical studies and agency evaluations, and give added support and means to pharma firms, permitting them to develop the newest therapies more easily this is the point where NSCLC comes in. Timely access to the most effective therapies can really make a difference in patients' lives. As a consequence of more number of new biomarkers and treatment modalities being recognized, regulatory agencies are willing to approve drugs based on surrogate endpoints, thus quickening their processes even further.

A positive regulatory environment affords innovation and investment in NSCLC research. Thus companies have the opportunity to develop new drugs and explore untapped therapeutic pathways. As a consequence, the spectrum of NSCLC treatments is changing at a rapid pace and there is a growing number of drug options with proven efficacy to be used by patients in need.

Targeted Therapy Type Segment Driving Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Growth

Non Small Cell Lung Cancer Therapeutics Market By Type

The rise of targeted therapy is a major factor in the expansion of the non-small cell lung cancer (NSCLC) therapeutics market. It is largely due to the targeted therapy segment's ability to give patients less harmful and more personalized treatment options. In contradictinction to chemotherapy, which is general and affects both cancer cells and healthy ones, targeted therapies pinpoint the molecular targets that are specifically associated with the tumor growth. Thus, treatment effectiveness is raised through precision, at the same time, the side-effects are reduced, thereby extending the patients' quality of life.

Additionally, the detection of mutations that can be acted upon, for example, EGFR, ALK, and ROS1, has led to the invention of targeted agents that can, in a remarkable way, increase the lifespans of a particular group of patients. Genetic testing to find these types of mutations is turning more common.

On top of that, the clinical trials that are underway keep finding new targets as well as new combinations and, therefore, the total number of therapies that are available is increasing. The good results of the current targeted treatments have been the main reason for the investment in the research and development of new drugs. Consequently, the targeted therapy segment, apart from leading the shift in treatment span of NSCLC, is also responsible for the growth of the therapeutics market in general.

Regional Outlook of Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market

Non Small Cell Lung Cancer Therapeutics Market By Region

Attribute	Detail
Leading Region	North America

North America is a major contributor to the non-small cell lung cancer (NSCLC) therapeutics market, holding the largest revenue share of 40.2%, due to a bunch of reasons. It is primarily equipped with an advanced healthcare infrastructure that quickly reaches out to the utmost modern therapies and instruments. The U.S. pharmaceutical and biotech industries, being the powerhouses of the world, have a positive effect on the evolution of new next-generation biologic and small-molecule agents, including targeted and immunotherapeutic agents, as they stimulate and expedite the process of innovation.

Moreover, a lot of research and clinical trials are being conducted in North America, which gradually pulls in a long list of treatments for NSCLC. FDA, as an example, is very efficient and fast in facilitating the phases of new drug development with fast-track designations and breakthrough therapy approvals, thus the market access of the most promising therapies is quick. The investment and the collaboration between stakeholders is very active and efficient, thanks to the regulatory environment that supports those acts.

Furthermore, the prevalence of NSCLC in North America is high, thus the demand for efficacious therapeutics is high as well, and the main reasons for this prevalence are cigarette smoking and air pollution. The general public's awareness and early diagnosis through screening programs raise the treatment levels as well. At last, the region's strong emphasis on the application of personalized medicine paves the way for patient-specific treatment plans which, thus, lead to better results. Altogether, these factors make North America a giant in the field of NSCLC therapeutics and thus, a continuing trend of growth and innovation is expected in the future.

Analysis of Key Players in Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market

F. Hoffmann-La Roche AG, Eli Lilly and Company, Amgen Inc., Bristol Myers Squibb, Boehringer Ingelheim International GmbH, Genentech, Inc., Pfizer Inc., AstraZeneca, Janssen Biotech, Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Xcovery Holdings, Inc., Merck KGaA, Merus N.V., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, GSK plc, Bayer AG, Astellas, Shanghai Henlius Biotech are the key players governing the global non-small cell lung cancer (NSCLC) therapeutics market.

Each of these players has been profiled in the non-small cell lung cancer (NSCLC) therapeutics industry research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments

In March 2025, AstraZeneca announced the acquisition of Belgian biotech EsoBiotec for up to US$1 billion, to expand its oncology & immunotherapy portfolio, including lung-cancer immunotherapy assets.
In January 2025, the US Food and Drug Administration (FDA) granted priority review to Dizal's new drug application (NDA) for Sunvozertinib, targeting the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients.
In December 2024, Merus N.V. announced that the FDA had approved BIZENGRI (zenocutuzumab-zbco), the first and only treatment for adults with advanced unresectable or metastatic pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion, who have experienced disease progression after prior systemic therapy.

Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Snapshot

Attribute	Detail
Size in 2024	US$ 22.3 Bn
Forecast Value in 2035	More than US$ 81.9 Bn
CAGR	12.6%
Forecast Period	2025-2035
Historical Data Available for	2020-2023
Quantitative Units	US$ Bn for Value
Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis.
Competition Landscape	Competition Matrix Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Segmentation	By Therapy Type Targeted Therapy Immunotherapy Chemotherapy By Drug Class Vascular Endothelial Growth Factor (VEGF) Inhibitors KRAS Inhibitors Epidermal Growth Factor Receptor (EGFR) Inhibitors Anaplastic lymphoma kinase (ALK) Inhibitors ROS1 Inhibitors BRAF Inhibitors MET Inhibitors Others (RET Inhibitors, TRK Inhibitors, HER2 Inhibitors, etc.) By Route of Administration Oral Parenteral Others (Inhalation, etc.) By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain The Netherlands China India Japan South Korea Australia ASEAN Brazil Mexico Argentina GCC Countries South Africa
Companies Profiled	F. Hoffmann-La Roche Ltd. Eli Lilly and Company Amgen Inc. Bristol Myers Squibb Boehringer Ingelheim International GmbH Genentech, Inc. Pfizer Inc. AstraZeneca Janssen Biotech, Inc. Takeda Pharmaceutical Company Limited Novartis AG Xcovery Holdings, Inc. Merck KGaA Merus N.V. Mylan N.V. Teva Pharmaceutical Industries Ltd. Sanofi GSK plc Bayer AG Astellas Shanghai Henlius Biotech Other Prominent Players
Customization Scope	Available upon request
Pricing	Available upon request

Frequently Asked Questions

How big was the global non-small cell Lung cancer (NSCLC) therapeutics market in 2024?

It was valued at US$ 22.3 Bn in 2024

What is the projected size of the non-small cell Lung cancer (NSCLC) therapeutics market by 2035?

It is projected to cross US$ 81.9 Bn by the end of 2035

What are the factors driving the non-small cell Lung cancer (NSCLC) therapeutics market?

Advancements in targeted therapies and regulatory approvals and fast-track designations

What is the non-small cell Lung cancer (NSCLC) therapeutics market expected to grow during the forecast period?

It is anticipated to grow at a CAGR of 12.6% from 2025 to 2035

Which region is expected to dominate the non-small cell Lung cancer (NSCLC) therapeutics market during the forecast period?

North America is expected to account for the largest share from 2025 to 2035

Who are the prominent non-small cell Lung cancer (NSCLC) therapeutics providers?

F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen Inc., Bristol Myers Squibb, Boehringer Ingelheim International GmbH, Genentech, Inc., Pfizer Inc., AstraZeneca, Janssen Biotech, Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Xcovery Holdings, Inc., Merck KGaA, Merus N.V., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, GSK plc, Bayer AG, Astellas, Shanghai Henlius Biotech, and others

Preface
- Market Definition and Scope
- Market Segmentation
- Key Research Objectives
- Research Highlights
Assumptions and Research Methodology
Executive Summary: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market
Market Overview
- Introduction
  - Segment Definition
  - Industry Evolution / Developments
- Overview
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunities
- Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis and Forecast, 2020-2035
  - Market Revenue Projections (US$ Bn)
  - Market Volume Projections (Units)
Key Insights
- Regulatory Scenario by Region/Country
- Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
- PORTER’s Five Forces Analysis
- PESTEL Analysis
- Supply Chain Analysis
- Timeline for FDA Approval of Non-Small Cell Lung Cancer Therapeutics
- Key Product/Brand Analysis
- Treatment Options and Algorithm
- Reimbursement Scenario by Region/Country
- Pipeline Analysis
- Pricing Analysis (Brand pricing, Average Selling Price by Region/Country)
- Disease Prevalence & Incidence Rate by Region/Country
Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis and Forecast, by Therapy Type
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Therapy Type, 2020-2035
  - Targeted Therapy
  - Immunotherapy
  - Chemotherapy
- Market Attractiveness Analysis, by Therapy Type
Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis and Forecast, by Drug Class
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Drug Class, 2020-2035
  - Vascular Endothelial Growth Factor (VEGF) Inhibitors
  - KRAS Inhibitors
  - Epidermal Growth Factor Receptor (EGFR) Inhibitors
  - Anaplastic lymphoma kinase (ALK) Inhibitors
  - ROS1 Inhibitors
  - BRAF Inhibitors
  - MET Inhibitors
  - Others
- Market Attractiveness Analysis, by Drug Class
Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis and Forecast, by Route of Administration
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Route of Administration, 2020-2035
  - Oral
  - Parenteral
  - Others
- Market Attractiveness Analysis, by Route of Administration
Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis and Forecast, by Distribution Channel
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Distribution Channel, 2020-2035
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- Market Attractiveness Analysis, by Distribution Channel
Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis and Forecast, by Region
- Key Findings
- Market Value Forecast, by Region, 2020-2035
  - North America
  - Europe
  - Asia Pacific
  - Latin America
  - Middle East & Africa
- Market Attractiveness Analysis, by Region
North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Therapy Type, 2020-2035
  - Targeted Therapy
  - Immunotherapy
  - Chemotherapy
- Market Value Forecast, by Drug Class, 2020-2035
  - Vascular Endothelial Growth Factor (VEGF) Inhibitors
  - KRAS Inhibitors
  - Epidermal Growth Factor Receptor (EGFR) Inhibitors
  - Anaplastic lymphoma kinase (ALK) Inhibitors
  - ROS1 Inhibitors
  - BRAF Inhibitors
  - MET Inhibitors
  - Others
- Market Value Forecast, by Route of Administration, 2020-2035
  - Oral
  - Parenteral
  - Others
- Market Value Forecast, by Distribution Channel, 2020-2035
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - U.S.
  - Canada
- Market Attractiveness Analysis
  - By Therapy Type
  - By Drug Class
  - By Route of Administration
  - By Distribution Channel
  - By Country/Sub-region
Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Therapy Type, 2020-2035
  - Targeted Therapy
  - Immunotherapy
  - Chemotherapy
- Market Value Forecast, by Drug Class, 2020-2035
  - Vascular Endothelial Growth Factor (VEGF) Inhibitors
  - KRAS Inhibitors
  - Epidermal Growth Factor Receptor (EGFR) Inhibitors
  - Anaplastic lymphoma kinase (ALK) Inhibitors
  - ROS1 Inhibitors
  - BRAF Inhibitors
  - MET Inhibitors
  - Others
- Market Value Forecast, by Route of Administration, 2020-2035
  - Oral
  - Parenteral
  - Others
- Market Value Forecast, by Distribution Channel, 2020-2035
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - The Netherlands
  - Rest of Europe
- Market Attractiveness Analysis
  - By Therapy Type
  - By Drug Class
  - By Route of Administration
  - By Distribution Channel
  - By Country/Sub-region
Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Therapy Type, 2020-2035
  - Targeted Therapy
  - Immunotherapy
  - Chemotherapy
- Market Value Forecast, by Drug Class, 2020-2035
  - Vascular Endothelial Growth Factor (VEGF) Inhibitors
  - KRAS Inhibitors
  - Epidermal Growth Factor Receptor (EGFR) Inhibitors
  - Anaplastic lymphoma kinase (ALK) Inhibitors
  - ROS1 Inhibitors
  - BRAF Inhibitors
  - MET Inhibitors
  - Others
- Market Value Forecast, by Route of Administration, 2020-2035
  - Oral
  - Parenteral
  - Others
- Market Value Forecast, by Distribution Channel, 2020-2035
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - China
  - India
  - Japan
  - South Korea
  - ASEAN
  - Australia & New Zealand
  - Rest of Asia Pacific
- Market Attractiveness Analysis
  - By Therapy Type
  - By Drug Class
  - By Route of Administration
  - By Distribution Channel
  - By Country/Sub-region
Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Therapy Type, 2020-2035
  - Targeted Therapy
  - Immunotherapy
  - Chemotherapy
- Market Value Forecast, by Drug Class, 2020-2035
  - Vascular Endothelial Growth Factor (VEGF) Inhibitors
  - KRAS Inhibitors
  - Epidermal Growth Factor Receptor (EGFR) Inhibitors
  - Anaplastic lymphoma kinase (ALK) Inhibitors
  - ROS1 Inhibitors
  - BRAF Inhibitors
  - MET Inhibitors
  - Others
- Market Value Forecast, by Route of Administration, 2020-2035
  - Oral
  - Parenteral
  - Others
- Market Value Forecast, by Distribution Channel, 2020-2035
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Market Attractiveness Analysis
  - By Therapy Type
  - By Drug Class
  - By Route of Administration
  - By Distribution Channel
  - By Country/Sub-region
Middle East & Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Therapy Type, 2020-2035
  - Targeted Therapy
  - Immunotherapy
  - Chemotherapy
- Market Value Forecast, by Drug Class, 2020-2035
  - Vascular Endothelial Growth Factor (VEGF) Inhibitors
  - KRAS Inhibitors
  - Epidermal Growth Factor Receptor (EGFR) Inhibitors
  - Anaplastic lymphoma kinase (ALK) Inhibitors
  - ROS1 Inhibitors
  - BRAF Inhibitors
  - MET Inhibitors
  - Others
- Market Value Forecast, by Route of Administration, 2020-2035
  - Oral
  - Parenteral
  - Others
- Market Value Forecast, by Distribution Channel, 2020-2035
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - GCC Countries
  - South Africa
  - Rest of Middle East & Africa
- Market Attractiveness Analysis
  - By Therapy Type
  - By Drug Class
  - By Route of Administration
  - By Distribution Channel
  - By Country/Sub-region
Competition Landscape
- Market Player - Competition Matrix (By Tier and Size of Companies)
- Market Share Analysis, by Company (2024)
- Company Profiles
  - F. Hoffmann-La Roche Ltd.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Eli Lilly and Company
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Amgen Inc.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Bristol Myers Squibb
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Boehringer Ingelheim International GmbH
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Genentech, Inc.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Pfizer Inc.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - AstraZeneca
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Janssen Biotech, Inc.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Takeda Pharmaceutical Company Limited
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Novartis AG
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Xcovery Holdings, Inc.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Merck KGaA
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Merus N.V.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Mylan N.V.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Teva Pharmaceutical Industries Ltd.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Sanofi
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - GSK plc
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Bayer AG
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Astellas
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Shanghai Henlius Biotech
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Other Prominent Players
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments

List of Tables

Table 01: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Therapy Type, 2020 to 2035
Table 02: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2020 to 2035
Table 03: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Route of Administration, 2020 to 2035
Table 04: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Distribution Channel, 2020 to 2035
Table 05: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Region, 2020 to 2035
Table 06: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Therapy Type, 2020 to 2035
Table 07: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2020 to 2035
Table 08: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Route of Administration, 2020 to 2035
Table 09: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Distribution Channel, 2020 to 2035
Table 10: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Region, 2020 to 2035
Table 11: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Therapy Type, 2020 to 2035
Table 12: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2020 to 2035
Table 13: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Route of Administration, 2020 to 2035
Table 14: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Distribution Channel, 2020 to 2035
Table 15: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Region, 2020 to 2035
Table 16: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Therapy Type, 2020 to 2035
Table 17: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2020 to 2035
Table 18: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Route of Administration, 2020 to 2035
Table 19: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Distribution Channel, 2020 to 2035
Table 20: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Region, 2020 to 2035
Table 21: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Therapy Type, 2020 to 2035
Table 22: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2020 to 2035
Table 23: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Route of Administration, 2020 to 2035
Table 24: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Distribution Channel, 2020 to 2035
Table 25: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Region, 2020 to 2035
Table 26: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Therapy Type, 2020 to 2035
Table 27: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2020 to 2035
Table 28: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Route of Administration, 2020 to 2035
Table 29: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Distribution Channel, 2020 to 2035
Table 30: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, by Region, 2020 to 2035

List of Figures

Figure 01: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 02: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2024 and 2035
Figure 03: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2025 to 2035
Figure 04: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by Targeted Therapy, 2020 to 2035
Figure 05: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by Immunotherapy, 2020 to 2035
Figure 06: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by Chemotherapy, 2020 to 2035
Figure 07: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Drug Class, 2024 and 2035
Figure 08: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Drug Class, 2025 to 2035
Figure 09: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by Vascular Endothelial Growth Factor (VEGF) Inhibitors, 2020 to 2035
Figure 10: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by KRAS Inhibitors, 2020 to 2035
Figure 11: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by Epidermal Growth Factor Receptor (EGFR) Inhibitors, 2020 to 2035
Figure 12: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by Anaplastic lymphoma kinase (ALK) Inhibitors, 2020 to 2035
Figure 13: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by ROS1 Inhibitors, 2020 to 2035
Figure 14: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by BRAF Inhibitors, 2020 to 2035
Figure 15: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by MET Inhibitors, 2020 to 2035
Figure 16: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 17: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2024 and 2035
Figure 18: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2025 to 2035
Figure 19: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by Oral, 2020 to 2035
Figure 20: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by Parenteral, 2020 to 2035
Figure 21: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 22: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2024 and 2035
Figure 23: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2025 to 2035
Figure 24: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by Hospital Pharmacies, 2020 to 2035
Figure 25: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by Retail Pharmacies, 2020 to 2035
Figure 26: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Revenue (US$ Bn), by Online Pharmacies, 2020 to 2035
Figure 27: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Region, 2024 and 2035
Figure 28: Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Region, 2025 to 2035
Figure 29: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 30: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2024 and 2035
Figure 31: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2025 to 2035
Figure 32: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Drug Class, 2024 and 2035
Figure 33: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Drug Class, 2025 to 2035
Figure 34: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2024 and 2035
Figure 35: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2025 to 2035
Figure 36: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2024 and 2035
Figure 37: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2025 to 2035
Figure 38: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Region, 2024 and 2035
Figure 39: North America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Region, 2025 to 2035
Figure 40: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 41: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2024 and 2035
Figure 42: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2025 to 2035
Figure 43: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Drug Class, 2024 and 2035
Figure 44: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Drug Class, 2025 to 2035
Figure 45: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2024 and 2035
Figure 46: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2025 to 2035
Figure 47: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2024 and 2035
Figure 48: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2025 to 2035
Figure 49: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Region, 2024 and 2035
Figure 50: Europe Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Region, 2025 to 2035
Figure 51: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 52: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2024 and 2035
Figure 53: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2025 to 2035
Figure 54: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Drug Class, 2024 and 2035
Figure 55: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Drug Class, 2025 to 2035
Figure 56: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2024 and 2035
Figure 57: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2025 to 2035
Figure 58: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2024 and 2035
Figure 59: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2025 to 2035
Figure 60: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Region, 2024 and 2035
Figure 61: Asia Pacific Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Region, 2025 to 2035
Figure 62: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 63: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2024 and 2035
Figure 64: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2025 to 2035
Figure 65: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Drug Class, 2024 and 2035
Figure 66: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Drug Class, 2025 to 2035
Figure 67: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2024 and 2035
Figure 68: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2025 to 2035
Figure 69: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2024 and 2035
Figure 70: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2025 to 2035
Figure 71: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Region, 2024 and 2035
Figure 72: Latin America Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Region, 2025 to 2035
Figure 73: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 74: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2024 and 2035
Figure 75: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2025 to 2035
Figure 76: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Drug Class, 2024 and 2035
Figure 77: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Drug Class, 2025 to 2035
Figure 78: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2024 and 2035
Figure 79: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2025 to 2035
Figure 80: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2024 and 2035
Figure 81: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2025 to 2035
Figure 82: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Value Share Analysis, by Region, 2024 and 2035
Figure 83: Middle East and Africa Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Attractiveness Analysis, by Region, 2025 to 2035